Evidence map›Paper›PMID 37271500›Full record

ArticleJournal of the peripheral nervous system : JPNS2023

Recruiting for an International Rare Disease Clinical Trial Readiness Study during the COVID-19 pandemic: Challenges and solutions.

Katy Eichinger, Steffen Behrens-Spraggins, Janet E Sowden, Davide Pareyson, Mary M Reilly, Steven S Scherer, Michael E Shy, David N Herrmann, ACT-CMT Study Group

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the peripheral nervous system : JPNS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katy EichingerDepartment of Neurology, University of Rochester, Rochester, New York, USA.ORCID 0000-0003-4623-7014
Steffen Behrens-SpragginsDepartment of Neurology, University of Rochester, Rochester, New York, USA.
Janet E SowdenDepartment of Neurology, University of Rochester, Rochester, New York, USA.
Davide PareysonDepartment of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID 0000-0001-6854-765X
Mary M ReillyCentre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Steven S SchererDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3900-2367
Michael E ShyDepartment of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
David N HerrmannDepartment of Neurology, University of Rochester, Rochester, New York, USA.
ACT-CMT Study Group

Funding

Accelerate Clinical Trials in CMT (ACTCMT) StudyU01NS109403 · NINDS · UNIVERSITY OF ROCHESTER · PI HERRMANN, DAVID N · 2019 to 2023
$6.4M
NIH HHS 5U01NS109403-05NINDS NIH HHS U01 NS109403
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clinical Trials as TopicCOVID-19HumansPandemicsRare Diseases

Identifiers

PMID37271500
PMCPMC13345707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.